Compare · DFTX vs SNDL
DFTX vs SNDL
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and SNDL Inc. (SNDL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and SNDL operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.76B, about 14.4x SNDL ($330.6M).
- Over the past year, DFTX is up 353.3% and SNDL is down 23.0% - DFTX leads by 376.3 points.
- DFTX has been more active in the news (7 items in the past 4 weeks vs 2 for SNDL).
- DFTX has more recent analyst coverage (5 ratings vs 4 for SNDL).
PerformanceDFTX+353.27%SNDL-23.03%
2025-07-22+0.00%2026-07-22
- Company
- Definium Therapeutics Inc.
- SNDL Inc.
- Price
- $43.70-2.96%
- $1.27-1.17%
- Market cap
- $4.76B
- $330.6M
- 1M return
- +19.12%
- -9.29%
- 1Y return
- +353.27%
- -23.03%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 7
- 2
- Recent ratings
- 5
- 4
SNDL
SNDL Inc.
Sundial Growers Inc. engages in production and marketing of cannabis products for the adult-use market in Canada. It produces and distributes inhalable products, such as flower, pre-rolls, and vapes. The company offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. Sundial Growers Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.
Latest DFTX
- A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
- Definium Therapeutics Announces New Employee Inducement Grants
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
- New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
- Definium Therapeutics Announces New Employee Inducement Grants
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Chief Legal Officer Sullivan Mark sold $585,750 worth of shares (13,008 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 320,571 units (SEC Form 4) (withholding tax)
- Chief Medical Officer Karlin Daniel sold $451,876 worth of shares (10,035 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 503,282 units (SEC Form 4) (withholding obligation)
- Chief Financial Officer Roberts Brandi sold $135,675 worth of shares (3,013 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 209,487 units (SEC Form 4) (withholding obligation)
Latest SNDL
- SEC Form 6-K filed by SNDL Inc.
- SNDL to Report Second Quarter 2026 Financial Results on July 28, 2026
- SNDL Announces Update on Arrangement Agreement with 1CM for Acquisition of Ontario Cannabis Stores
- SEC Form 6-K filed by SNDL Inc.
- SNDL Reports First Quarter 2026 Financial and Operational Results
- SEC Form 6-K filed by SNDL Inc.
- SEC Form 6-K filed by SNDL Inc.
- SNDL to Report First Quarter 2026 Financial Results on April 29, 2026
- SEC Form 6-K filed by SNDL Inc.
- SNDL Announces Leadership Transition for Cannabis Segment